Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about GSK plc
Recent news which mentions GSK plc
< Previous
1
2
Next >
Trump's drug price ultimatum sets pharma firms scrambling
August 01, 2025
Tags
Biotechnology
AstraZeneca PLC
Eli Lilly and Co
From
CNBC.com News
Trump's pharmaceutical tariffs could affect some drugmakers more than others
July 29, 2025
Tags
AbbVie Inc
Pharmaceuticals
Business News
From
CNBC.com News
FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
June 18, 2025
Tags
Breaking News: Business
Business News
Pharmaceuticals
From
CNBC.com News
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
June 17, 2025
Tags
AstraZeneca PLC
Companies
Biotechnology
From
CNBC.com News
FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
June 09, 2025
Tags
Pfizer Inc
US: News
Health care industry
From
CNBC.com News
Denmark's economy is booming on drug exports — Trump's tariffs threat won't slow it down
May 15, 2025
Tags
Roche Holding AG
Novo Nordisk A/S
AstraZeneca PLC
From
CNBC.com News
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
April 30, 2025
Tags
Abbott Laboratories
Roche Holding AG
Biotech and Pharmaceuticals
From
CNBC.com News
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
April 09, 2025
Tags
Regeneron Pharmaceuticals Inc
GSK plc
Amgen Inc
From
CNBC.com News
The biggest winners and losers in Europe as Trump announces sweeping tariffs
April 03, 2025
Tags
World News
Standard Chartered PLC
AstraZeneca PLC
From
CNBC.com News
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
April 01, 2025
Tags
Amgen Inc
LILLY DRN
GSK plc
From
CNBC.com News
Cramer's Lightning Round: 'You've got a winner in Cheesecake Factory'
March 04, 2025
Tags
Investing
Market Outlook
Investment strategy
From
CNBC.com News
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
February 04, 2025
Tags
Pharmaceuticals
Novavax Inc
Biontech SE
From
CNBC.com News
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
January 26, 2025
Tags
Pharmaceuticals
Business News
GSK plc
From
CNBC.com News
Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
January 17, 2025
Tags
Biotechnology
US: News
Novo Nordisk A/S
From
CNBC.com News
Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals
January 14, 2025
Tags
Accolade Inc
BridgeBio Pharma Inc
Madrigal Pharmaceuticals Inc
From
CNBC.com News
Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS
November 14, 2024
Tags
Biotech and Pharmaceuticals
Moderna Inc
Business
From
CNBC.com News
Wednesday's big stock stories: What’s likely to move the market in the next trading session
October 29, 2024
Tags
KB Home
PRO: Playbooks
Microsoft Corp
From
CNBC.com News
Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
October 17, 2024
Tags
Business
Biotech and Pharmaceuticals
Pfizer Inc
From
CNBC.com News
Healthy Returns: Weight loss drug Wegovy could face Medicare price negotiations next
September 24, 2024
Tags
Biotech and Pharmaceuticals
Novo Nordisk A/S
Social issues
From
CNBC.com News
Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future
September 12, 2024
Tags
Breaking News: Business
GSK plc
Health & Science
From
CNBC.com News
Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market
August 01, 2024
Tags
Pfizer Inc
US: News
Breaking News: Earnings
From
CNBC.com News
Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
June 28, 2024
Tags
Business
Vaccinations
Labor economy
From
CNBC.com News
FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections
June 17, 2024
Tags
Pfizer Inc
US: News
Health care industry
From
CNBC.com News
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
June 07, 2024
Tags
Biotech and Pharmaceuticals
Moderna Inc
Science
From
CNBC.com News
Pharma giant GSK plunges 9% after U.S. court allows scientific testimony in Zantac lawsuits
June 03, 2024
Tags
Markets
World Markets
Sanofi SA
From
CNBC.com News
FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
May 31, 2024
Tags
Health care industry
Biotechnology
Companies
From
CNBC.com News
Moderna says FDA delayed RSV vaccine approval to end of May
May 10, 2024
Tags
Pharmaceuticals
Breaking news
Business News
From
CNBC.com News
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
April 30, 2024
Tags
Teva Pharmaceutical Industries Ltd
Breaking News: Politics
Health & Science
From
CNBC.com News
Pfizer's RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
April 09, 2024
Tags
Respiratory syncytial virus
GSK plc
Health & Science
From
CNBC.com News
Healthy Returns: Drugmakers are capping inhaler prices at $35 in a win for some patients
March 26, 2024
Tags
Healthy Returns
AstraZeneca PLC
Health & Science
From
CNBC.com News
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.